Patents by Inventor David Chih-Kuang CHOU

David Chih-Kuang CHOU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE
    Publication number: 20240024407
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Application
    Filed: June 12, 2023
    Publication date: January 25, 2024
    Inventor: David Chih-Kuang Chou
  • METHOD FOR TREATING ACUTE ISCHEMIC STROKE
    Publication number: 20240016794
    Abstract: The present invention is directed to a method of treating acute ischemic stroke in a human comprising administering one of more low doses of DC009, wherein the dose is about 0.01-0.075 mg/kg/dose. The low dose administration is safe and effective in treating acute ischemic stroke in a human subject.
    Type: Application
    Filed: September 20, 2023
    Publication date: January 18, 2024
    Inventors: David Chih-Kuang Chou, Jung-Chin Lin, Sheng-Wen Yeh, Shiqi Peng, Ming Zhao
  • Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
    Patent number: 11707501
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: July 25, 2023
    Assignee: LUMOSA THERAPEUTICS CO., LTD
    Inventor: David Chih-Kuang Chou
  • PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE
    Publication number: 20220370542
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Application
    Filed: May 23, 2022
    Publication date: November 24, 2022
    Inventor: David Chih-Kuang Chou
  • COMPOSITIONS AND METHODS FOR TREATING PRURITUS
    Publication number: 20220362226
    Abstract: Disclosed herein are topical pharmaceutical compositions of Sebacoyl Dinalbuphine Ester (SDE) and methods of using such compositions for treating pruritus, pain, and inflammatory conditions.
    Type: Application
    Filed: April 29, 2022
    Publication date: November 17, 2022
    Inventors: Wendy Huang CHERN, Chan-Jung LI, Shu-Wen KUO, David Chih-Kuang CHOU, Yu-En TIEN
  • Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate
    Patent number: 11338008
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: May 24, 2022
    Assignee: LUMOSA THERAPEUTICS CO., LTD
    Inventor: David Chih-Kuang Chou
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20220071987
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: September 22, 2021
    Publication date: March 10, 2022
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
    Patent number: 11241424
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Grant
    Filed: December 30, 2019
    Date of Patent: February 8, 2022
    Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.
    Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr Tsai, Shu-Wen Kuo, Yu-En Tien
  • Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
    Patent number: 11234974
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: February 1, 2022
    Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.
    Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr. Tsai, Shu-Wen Kuo, Yu-En Tien
  • TOPICAL COMPOSITION OF NALBUPHINE AND METHOD FOR TREATING PRURITUS CONDITION, PAIN, OR INFLAMMATORY CONDITION BY USING THE SAME
    Publication number: 20210330667
    Abstract: Provided is a topical composition of nalbuphine, comprising nalbuphine or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient comprising a penetration enhancer, a thickening agent, a solvent, or any combination thereof. Also provided are a kit comprising a unit dosage of the topical composition of nalbuphine and a method treating pruritus condition, pain, or inflammatory condition by using the topical composition of nalbuphine.
    Type: Application
    Filed: July 7, 2021
    Publication date: October 28, 2021
    Inventors: David Chih-Kuang CHOU, Chia-yin LU
  • PHARMACEUTICAL COMPOSITION COMPRISING THROMBOLYTIC PEPTIDE-TETRAHYDROISOQUINOLINE CONJUGATE
    Publication number: 20210085747
    Abstract: The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.
    Type: Application
    Filed: September 24, 2020
    Publication date: March 25, 2021
    Inventor: David Chih-Kuang CHOU
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20200179373
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: February 18, 2020
    Publication date: June 11, 2020
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20200179372
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: December 30, 2019
    Publication date: June 11, 2020
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20200030318
    Abstract: The present invention relates to kits and prefilled syringes comprising pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as methods of treating pain using such formulations.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 30, 2020
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr TSAI, Shu-Wen KUO, Yu-En TIEN
  • COMPOSITIONS AND METHODS FOR TREATING PRURITUS
    Publication number: 20190298702
    Abstract: Disclosed herein are topical pharmaceutical compositions of Sebacoyl Dinalbuphine Ester (SDE) and methods of using such compositions for treating pruritus, pain, and inflammatory conditions.
    Type: Application
    Filed: March 28, 2019
    Publication date: October 3, 2019
    Inventors: Wendy Huang Chern, Chan-Jung Li, Shu-Wen Kuo, David Chih-Kuang Chou, Yu-En Tien
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20190160053
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: November 19, 2018
    Publication date: May 30, 2019
    Inventors: Chan-Jung LI, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr Tsai, Shu-Wen Kuo, Yu-En Tien
  • Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester
    Patent number: 10183018
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: January 22, 2019
    Assignees: Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.
    Inventors: Chan-Jung Li, David Chih-Kuang Chou, Jin-Ding Huang, Shin-Jr. Tsai, Shu-Wen Kuo, Yu-En Tien
  • PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE OF SEBACOYL DINALBUPHINE ESTER
    Publication number: 20160346275
    Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 1, 2016
    Inventors: Chan-Jung LI, David Chih-Kuang CHOU, Jin-Ding HUANG, Shin-Jr. TSAI, Shu-Wen KUO, Yu-En TIEN